Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis
36:06
A Challenging Odyssey through AML: Confronting aGvHD, TMA, PRES after alloHCT
53:00
Multiple Myeloma: Highlights from #ASH24
35:56
AL30: ¿Tomar Ganancias o Ir por AE38?
49:06
Post #ASH24 Most Important CLL Studies
1:12:49
Probióticos, piel y sistema inmune: medicina del futuro | Dr. John Gaviria
1:04:30
Utilidad de las Células CART-T
43:48
Post #ASH24 Most Important Cellular Therapy Studies
42:29